New cell therapy offers hope for tough anemia cases
NCT ID NCT07453836
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tests a new cell therapy called YTS109 for people with autoimmune hemolytic anemia that hasn't improved after at least three prior treatments. The therapy uses specially engineered immune cells to target and destroy the faulty cells causing the anemia. The study aims to check if the treatment is safe and works, with 13 participants receiving different doses. A second infusion may be possible if needed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOIMMUNE HEMOLYTIC ANEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Beijing GoBroad Boren Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a simple blood test predict clot risk in antiphospholipid syndrome?
- Can a new drug calm the immune System's attack on blood cells?
- Engineered immune cells take aim at stubborn blood disorder
- Cheap drug combo may tame tough anemia
- Scientists hunt for genetic roots of rare childhood blood disorder
- New study aims to unlock the secrets of Children's rare blood diseases